Terms: = Thyroid cancer AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207
1092 results:
1. Biological functions of LncRNA SNHG14 in the development of thyroid cancer cells via targeting miR-206.
Sang Y; Min R; Huang T; Zhang J
Cell Mol Biol (Noisy-le-grand); 2024 Apr; 70(4):77-84. PubMed ID: 38678623
[TBL] [Abstract] [Full Text] [Related]
2. ANXA9 facilitates S100A4 and promotes breast cancer progression through modulating STAT3 pathway.
Zhou X; Zhao J; Yan T; Ye D; Wang Y; Zhou B; Liu D; Wang X; Zheng W; Zheng B; Qian F; Li Y; Li D; Fang L
Cell Death Dis; 2024 Apr; 15(4):260. PubMed ID: 38609357
[TBL] [Abstract] [Full Text] [Related]
3. The emerging role and clinical significance of circRNAs in papillary thyroid cancer.
Ma J; Xu J; Zhang X; Quan J
Front Endocrinol (Lausanne); 2024; 15():1351776. PubMed ID: 38544689
[TBL] [Abstract] [Full Text] [Related]
4. Osteopontin promotes tumor growth and metastasis and GPX4-mediated anti-lipid peroxidation in triple-negative breast cancer by activating the PI3k/akt/mTOR pathway.
Guo M; Liu M; Li W; Wang C; Zhang L; Zhang H
J Cancer Res Clin Oncol; 2024 Mar; 150(3):155. PubMed ID: 38526702
[TBL] [Abstract] [Full Text] [Related]
5. Morusin inhibits breast cancer-induced osteolysis by decreasing phosphatidylinositol 3-kinase (PI3K)-mTOR signalling.
Zhang L; Li W; Chen X; Cao D; You S; Shi F; Luo Z; Li H; Zeng X; Song Y; Li N; Akimoto Y; Rui G; Chen Y; Wu Z; Xu R
Chem Biol Interact; 2024 May; 394():110968. PubMed ID: 38522564
[TBL] [Abstract] [Full Text] [Related]
6. CD93 regulates breast cancer growth and vasculogenic mimicry through the PI3K/akt/SP2 signaling pathway activated by integrin β1.
Liu H; Zhang J; Zhao Y; Fan Z; Yang Y; Mao Y; Yang J; Ma S
J Biochem Mol Toxicol; 2024 Apr; 38(4):e23688. PubMed ID: 38511888
[TBL] [Abstract] [Full Text] [Related]
7. Hypoxia-induced miR-5100 promotes exosome-mediated activation of cancer-associated fibroblasts and metastasis of head and neck squamous cell carcinoma.
Duan Y; Zhou M; Ye B; Yue K; Qiao F; Wang Y; Lai Q; Wu Y; Cao J; Wu Y; Wang X; Jing C
Cell Death Dis; 2024 Mar; 15(3):215. PubMed ID: 38485986
[TBL] [Abstract] [Full Text] [Related]
8. GSG2 promotes thyroid cancer via stabilizing AURKB and activating akt pathway.
Zhang F; Huang C
Aging (Albany NY); 2024 Mar; 16(6):5091-5107. PubMed ID: 38441546
[TBL] [Abstract] [Full Text] [Related]
9. Bioinformatics analysis for the identification of Sprouty-related EVH1 domain-containing protein 3 expression and its clinical significance in thyroid carcinoma.
Zhang X; Meng X; Wang P; Luan C; Wang H
Sci Rep; 2024 Feb; 14(1):4549. PubMed ID: 38402263
[TBL] [Abstract] [Full Text] [Related]
10. TMEM97 knockdown inhibits 5-fluorouracil resistance by regulating epithelial-mesenchymal transition and ABC transporter expression via inactivating the akt/mTOR pathway in 5-fluorouracil-resistant colorectal cancer cells.
Xu Y; Tang Y; Xu Q; He W
Chem Biol Drug Des; 2024 Feb; 103(2):e14490. PubMed ID: 38388887
[TBL] [Abstract] [Full Text] [Related]
11. Deep response to a combination of mTOR inhibitor temsirolimus and dual immunotherapy of nivolumab/ipilimumab in poorly differentiated thyroid carcinoma with
Oh Y; Park JH; Djunadi TA; Shah Z; Chung LI; Chae YK
Front Endocrinol (Lausanne); 2024; 15():1304188. PubMed ID: 38356955
[TBL] [Abstract] [Full Text] [Related]
12. thyroid dysfunction caused by exposure to environmental endocrine disruptors and the underlying mechanism: A review.
He J; Xu J; Zheng M; Pan K; Yang L; Ma L; Wang C; Yu J
Chem Biol Interact; 2024 Mar; 391():110909. PubMed ID: 38340975
[TBL] [Abstract] [Full Text] [Related]
13. GBP2 enhances paclitaxel sensitivity in triple‑negative breast cancer by promoting autophagy in combination with ATG2 and inhibiting the PI3K/akt/mTOR pathway.
Zhang W; Tang X; Peng Y; Xu Y; Liu L; Liu S
Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38334171
[TBL] [Abstract] [Full Text] [Related]
14. Exploring CCL11 in breast cancer: unraveling its anticancer potential and immune modulatory effects involving the akt-S6 signaling.
Chen X; Meng C; Wang X; Wu Z; Sun X; Sun C; Zheng L; Li W; Jia W; Tang T
J Cancer Res Clin Oncol; 2024 Feb; 150(2):69. PubMed ID: 38305920
[TBL] [Abstract] [Full Text] [Related]
15. Systematic analysis of the role of LDHs subtype in pan-cancer demonstrates the importance of LDHD in the prognosis of hepatocellular carcinoma patients.
Wang S; Wu X; Wu X; Cheng J; Chen Q; Qi Z
BMC Cancer; 2024 Jan; 24(1):156. PubMed ID: 38291366
[TBL] [Abstract] [Full Text] [Related]
16. Bioinformatics analysis identifies coagulation factor II receptor as a potential biomarker in stomach adenocarcinoma.
Wu X; Wang S; Wang C; Wu C; Zhao Z
Sci Rep; 2024 Jan; 14(1):2468. PubMed ID: 38291086
[TBL] [Abstract] [Full Text] [Related]
17. GLP-1 receptor agonist liraglutide inhibits the proliferation and migration of thyroid cancer cells.
Zhang X; Zhang L; Wang B; Zhang X; Gu L; Guo K; Zhang X; Zhou Z
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):221-225. PubMed ID: 38279433
[TBL] [Abstract] [Full Text] [Related]
18. Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic transformation.
Lee M; Morris LG
Oncotarget; 2024 Jan; 15():36-48. PubMed ID: 38275291
[TBL] [Abstract] [Full Text] [Related]
19. SHMT2 promotes papillary thyroid cancer metastasis through epigenetic activation of akt signaling.
Sun M; Zhao M; Li R; Zhang Y; Shi X; Ding C; Ma C; Lu J; Yue X
Cell Death Dis; 2024 Jan; 15(1):87. PubMed ID: 38272883
[TBL] [Abstract] [Full Text] [Related]
20. A phase 1 study of triple-targeted therapy with BRAF, MEK, and akt inhibitors for patients with BRAF-mutated cancers.
Algazi AP; Moon J; Lao CD; Chmielowski B; Kendra KL; Lewis KD; Gonzalez R; Kim K; Godwin JE; Curti BD; Latkovic-Taber M; Lomeli SH; Gufford BT; Scumpia PO; Lo RS; Othus M; Ribas A
Cancer; 2024 May; 130(10):1784-1796. PubMed ID: 38261444
[TBL] [Abstract] [Full Text] [Related]
[Next]
